Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Valeant’s CEO Takes Medical Leave & Ex-CFO is Named Interim

By Meg Snyder | January 6, 2016

Chief Executive Officer, Michael Pearson, of Valeant Pharmaceuticals International Inc. has taken a medical leave of absence. In his stead, the company has named former Chief Financial Officer, Howard Schiller, as the interim CEO, while Bob Ingram will take the place of interim chairman.

Pearson has been hospitalized with severe pneumonia, and when he will return remains uncertain. The company officially disclosed Pearson’s hospitalization on Christmas Day.

From December 2011 through June 2015, Schiller served as the company’s CFO and is on its board of directors. But in June of 2015, he stepped down, saying he wished to “pursue new opportunities most likely in areas outside of a publicly-traded company.”

But this announcement doesn’t come at the best of times. 

According to a report from the FDA: “That team immediately faces a series of controversies—including congressional questions about its product pricing and an insider trading lawsuit.”

Before his illness, “Pearson had promised shareholders to provide more transparent data about Valeant’s business, including sales figures for its top 30 drugs,” according to Bloomberg Business. 

A press release from Winnipeg Free Press stated that: 

“The announcement comes as Valeant tries to overcome controversies that have slashed its stock price by more than half since it posted record highs in August.

Questions have mounted over whether Valeant became too big for its own good by embarking on a series of acquisitions in recent years while cutting research and development spending.

It has also faced accusations of drug price gouging and concerns were further raised about its previously undisclosed relationship with a U.S. mail-order pharmacy—an affiliation it later severed.

There were calls for Pearson to step down, but he was defiant, vowing to put the company’s troubles behind.”

Another source says that “Pearson’s medical leave doesn’t matter,” stating that the CEO can’t solve Valeant’s fundamental problem: that the company’s growth strategy is broken.

But, the story isn’t over yet. Hopefully, Pearson (and Valeant) will have a swift recovery. 

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE